Contract research organisation providing ion channel services to the drug discovery market.

Metrion Biosciences (Metrion) serve pharmaceutical and biotech clients to either perform cardiac screening services to understand if novel drug compounds have off-target effects or to develop new drug compounds that utilise ion channels.

Gresham House Ventures invested £2.25m as part of a £2.7m round. The investment will increase capacity, with enlarged lab facilities and specialist equipment; expand their service offering by adding a highly regulated GLP (Good Laboratory Practice) cardiac offering and expand their cell line library; and support further expansion in the United States. The investment continues our focus on outsourcing pharma services.

In December 2023, we topped up our investment by £1mn as part of a £3.7mn funding round.

Metrion has an experienced team providing a highly specialist service into a structurally growing market.

Investment rationale

Metrion has an experienced team providing a highly specialist service into a structurally growing market.

Investment team

Maya Ward

Investment Director

Maya joined Gresham House in September 2019, and focuses on healthcare investments, including Orri, Metrion Biosciences and Panthera Biopartners.

Prior to Gresham House, she spent 4 years at Octopus Investments, investing in real estate-backed healthcare companies and entrepreneurs. Before this she worked at KPMG for 7 years in audit and corporate finance.

Maya holds a first-class degree in Modern History and is a Chartered Accountant (ICAEW).

Outside of work, Maya enjoys playing hockey (when not suffering from an injury!), travelling and watching martial arts films.

It’s a pleasure to be investing in the future of UK healthcare across a range of sub sectors and working with some of the country’s top scientists and clinicians to deliver world-class solutions.

Example portfolio

orri logo orange

Brendan Gulston

Director, Public Equity

Brendan joined Gresham House in November 2018 having previously been at Livingbridge and is an integral part of our Public Equity team, as co-fund manager of the LF Gresham House UK Multi Cap Income Fund.

I love finding businesses where you can drive conviction early on, conclude a successful investment and continue to support them along the journey.

Brendan studied commerce with a focus on finance and subsequently spent four and a half years in technology investment banking at Canaccord Genuity.

Outside of work he enjoys skiing and is a big fan of the alpine lifestyle, as well as exploring new places, various creative pursuits and playing sport.

Example portfolio

Steve Carle

Operating Partner

Steve is an experienced private equity and development capital specialist having enjoyed a successful 30+ year career with the UK’s two leading mid-market private equity companies, and a specialist fund investing in the creative industries. He currently sits on the Boards of Metrion Biosciences and CitySwift on behalf of Gresham House Ventures.

After completing a law degree at Edinburgh University in 1991, Steve joined 3i where he worked in their Edinburgh and Cambridge offices.  In 1999 he left 3i to join LDC, the private equity arm of Lloyds Banking Group.  When Steve left LDC at the end of 2010, it had grown to become the UK’s leading mid-market private equity investor, and the deals which Steve led delivered near 100% gains on funds invested. After 5 years consulting and pursuing his own private investment activities, Steve joined Edge Investments, the UK’s leading creative industries investor where he served as both Chief Investment Officer and Portfolio Performance Director.  Returning to his consulting activities in 2021, Steve has worked with a number of PE investors, primarily in roles involving management of portfolio companies.

 

Example portfolio

CitySwift Colour Logo

Privacy Preference Center